Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Cancer
100%
Head and Neck Squamous Cell Carcinoma
90%
Epidermal Growth Factor Receptor
54%
Cetuximab
47%
Neoplasm
42%
Progression Free Survival
30%
Erlotinib
29%
Human Papillomavirus
28%
Overall Survival
26%
Non Small Cell Lung Cancer
26%
Biological Marker
26%
Malignant Neoplasm
25%
Squamous Cell Carcinoma
23%
Phase II Trials
23%
Disease
21%
Cisplatin
21%
Immunotherapy
18%
Clinical Trial
18%
Chemotherapy
16%
Chemoradiation Therapy
13%
Placebo
13%
Pemetrexed
11%
Monoclonal Antibody
11%
Adverse Event
10%
Docetaxel
10%
Imatinib
10%
Ficlatuzumab
10%
Phosphatidylinositol 3 Kinase Inhibitor
10%
Durvalumab
10%
Carcinogenesis
9%
Dasatinib
8%
Maximum Tolerated Dose
8%
Platelet Derived Growth Factor Receptor
8%
Solid Malignant Neoplasm
7%
Recurrent Disease
7%
Bevacizumab
7%
Mammalian Target of Rapamycin
7%
Non-Steroidal Anti-Inflammatory Drug
6%
Paclitaxel
6%
Monotherapy
6%
Tumor Growth
6%
CD8 Antigen
6%
Carcinogen
6%
Diarrhea
5%
Molecular Target
5%
Phosphotransferase
5%
Interleukin 6
5%
Tivantinib
5%
Detoxication
5%
Clinical Study
5%
Medicine and Dentistry
Head and Neck Cancer
93%
Head and Neck Squamous Cell Carcinoma
65%
Cetuximab
40%
Wart Virus
36%
Malignant Neoplasm
31%
Radiation Therapy
25%
Epidermal Growth Factor Receptor
24%
Immunotherapy
23%
Neoplasm
23%
Disease
20%
Non Small Cell Lung Cancer
20%
Overall Survival
19%
Phase II Trials
17%
Cisplatin
17%
Neck
16%
Oropharynx Squamous Cell Carcinoma
16%
Biological Marker
16%
Progression Free Survival
14%
Positron Emission Tomography
13%
Squamous Cell Carcinoma
13%
Arm
12%
Clinical Trial
12%
Oropharynx
11%
Chemoprophylaxis
11%
Pemetrexed
11%
Human Papillomavirus Type 16
11%
Imatinib
10%
Stereotactic Body Radiation Therapy
10%
Platelet Derived Growth Factor Receptor
8%
Base
7%
Gene Mutation
7%
Motolimod
7%
Re-Irradiation
7%
Xenograft
7%
Thyroid Cancer
7%
Bevacizumab
7%
Differentiated Thyroid Cancer
7%
Tongue
6%
Paclitaxel
6%
Larynx
6%
Toll Like Receptor 8
6%
Recurrent Disease
6%
Phosphotransferase
6%
Electrocorticography
6%
Nasopharynx Carcinoma
6%
Phase I Trials
6%
Induction Chemotherapy
5%
Adenocarcinoma
5%
Oncogene
5%
Thyroid Gland
5%
Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
66%
Head-and-neck Cancer
58%
Overall Survival
22%
Phase II Trial
22%
Cetuximab
21%
High-risk Human Papillomavirus (HR-HPV)
13%
Therapeutic Target
11%
Phosphatidylinositol 3-kinase Inhibitor
10%
Randomized Phase II Trial
10%
Docetaxel
10%
Neoadjuvant Chemotherapy
10%
PX-866
10%
Confidence Interval
10%
Non-small Cell Lung Cancer (NSCLC)
9%
Tumor
9%
Recurrent or Metastatic
9%
Objective Response Rate
8%
PIK3CA mutation
8%
Recurrent Metastatic
8%
Head-and-neck
8%
Progression-free Survival
7%
Human Papillomavirus Negative
7%
Cisplatin
7%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
6%
Nasopharyngeal Carcinoma
6%
Radiotherapy
6%
Epidermal Growth Factor Receptor
6%
PIK3CA
6%
EGFR Inhibition
6%
Dasatinib
5%
Phase II Clinical Trial
5%
PI3K Inhibitor
5%
Interleukin-6
5%
Gene Targeting
5%
Illness
5%
TP53 mutant
5%
Metnase
5%
Transoral Robotic Surgery
5%
Oropharyngeal Malignancy
5%
Biomarker Testing
5%
Late Toxicity
5%
Transnasal Endoscopy
5%
ASCO Guidelines
5%
Tivantinib
5%
Transoral Robotic
5%
Previously Treated
5%
Erlotinib
5%
Definitive Therapy
5%
Crosstalk Signal
5%
Sulforaphane
5%
